prod:prod_dcx-login
Xpert® C. difficile/Epi
45-minute detection & differentiation of Clostridium difficile & the Epidemic 027 strain
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
10 Tests
GXCDIFF/EPI-10
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Collection devices
Collection Device
900-0370
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Single Use Disposable Swab (Pack of 120)
SDPS-120
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Total
{{currency}}
0
Error adding items to cart. If this error persists, please contact Digital Support
The Need
Numerous outbreaks caused by the epidemic strain of C. difficile (027/NAP1/BI strain) highlight the need for rapid and accurate differentiation of C. difficile 027/NAP1/BI strains in order to stay ahead of an outbreak.
- Higher risk of cross contamination with 027/NAP1/BI strain due to more efficient sporulation1,2,3
- 027/NAP1/BI strain has been identified as a cause of outbreaks around the world4,5,6,7,8
- Incremental costs due to C. difficile infection can be as high as $7,1799 per patient
1. ÅkerlundT, et al. Increased Sporulation Rate of Epidemic Clostridium difficile Type 027/NAP1. J Clin Microbiol. Apr 2008, 46 (4) 1530-1533.
2. Warny M, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005 Sep 24-30;366(9491):1079-84.
3. Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med. 2006 Nov 21;145(10):758-64.
4. Kallen AJ, et al. Complete restriction of fluoroquinolone use to control an outbreak of Clostridium difficile infection at a community hospital. Infect Control Hosp Epidemiol. 2009 Mar;30(3):264-72.
5. Kuijper EJ, et al. Update of Clostridium difficile-associated Disease due to PCR Ribotype 027 in Europe. Eurosurveillance. Apr–Jun 2007. 12(3-6):163-166.
6. Muto CA, et al. Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive "bundle" approach. Clin Infect Dis. 2007 Nov 15;45(10):1266-73.
7. McDonald LC, et al. An Epidemic, Toxin Gene-variant Strain of Clostridium difficile. N Engl J Med. 2005 Dec 8;353(23):2433-41.
8. Loo VG, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005 Dec 8;353(23):2442
9. Jarvis WR, et al. National Point Prevalence of Clostridium difficile in US Health Care Facility Inpatients, 2008. Am J Infect Control. 2009 May;37(4):263-70.
10. Xpert® C. difficile/Epi Package Insert. 300-9680,Rev J. Apr 2020.
2. Warny M, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005 Sep 24-30;366(9491):1079-84.
3. Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med. 2006 Nov 21;145(10):758-64.
4. Kallen AJ, et al. Complete restriction of fluoroquinolone use to control an outbreak of Clostridium difficile infection at a community hospital. Infect Control Hosp Epidemiol. 2009 Mar;30(3):264-72.
5. Kuijper EJ, et al. Update of Clostridium difficile-associated Disease due to PCR Ribotype 027 in Europe. Eurosurveillance. Apr–Jun 2007. 12(3-6):163-166.
6. Muto CA, et al. Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive "bundle" approach. Clin Infect Dis. 2007 Nov 15;45(10):1266-73.
7. McDonald LC, et al. An Epidemic, Toxin Gene-variant Strain of Clostridium difficile. N Engl J Med. 2005 Dec 8;353(23):2433-41.
8. Loo VG, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005 Dec 8;353(23):2442
9. Jarvis WR, et al. National Point Prevalence of Clostridium difficile in US Health Care Facility Inpatients, 2008. Am J Infect Control. 2009 May;37(4):263-70.
10. Xpert® C. difficile/Epi Package Insert. 300-9680,Rev J. Apr 2020.
The Solution
Xpert C. difficile/Epi is the first commercially available test in the world to detect and differentiate the epidemic strain of C. difficile (027/NAP1/BI). With rapid and accurate identification of epidemic strain, Infection Control professional can stay ahead of potential outbreak situation.
- Innovative multiplex design enables detection of C. difficile Infection (CDI) and 027/NAP1/BI strain call-out in a single cartridge
- On-Demand testing of samples from suspected CDI patients provides On-Demand epidemiological surveillance data clinicians can act on
- Monitoring and reporting of the epidemic strain enables clinicians to improve infection control efforts
Related Products
Xpert MRSA NxG
Active MRSA surveillance testing in about an hour
Xpert SA Nasal Complete
Pre-surgical S. aureus and MRSA in about an hour
Xpert MRSA/SA Blood Culture
Accurate Detection of MRSA and SA in Positive Blood Culture Specimens in About an Hour
Xpert Norovirus
Fast and accurate identification of Norovirus GI & GII in as little as one hour* *With early assay termination for positive results. Reporting negative results in 90 minutes.
Xpert vanA
The first rapid & accurate test to assist with VRE surveillance
Xpert Carba-R
Detection and differentiation of KPC, NDM, VIM, IMP-1, and OXA-48 in 48 minutes
Xpert C. difficile
Detection of Clostridium difficile in 40 minutes*
Xpert MRSA/SA SSTI
Detect MRSA & SA Skin and Soft Tissue Infections In About One Hour